Morphic raises $51.5M for oral integrin inhibitors

Morphic Therapeutic (Waltham, Mass.) raised $51.5 million in a series A round co-led by SR One and Pfizer Venture Investments. Omega Funds and AbbVie Ventures also invested, along with existing investors Polaris Partners, chemical simulation software company Schroedinger Inc. (New York, N.Y.), ShangPharma Investment Group, and co-founder Timothy Springer.

The start-up is developing oral small molecule integrin inhibitors based on research out of Springer's lab. He is a professor at Harvard Medical School and Boston Children's Hospital. ...